BRANDON ALLEN: Open Payments
NPI 1073091963 · MERIDIAN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,541 in 27 payments from 11 companies in 2025. Trend: 2023 $433 · 2024 $955 · 2025 $1,541
Food & beverage: $1,541
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $319 |
| Axsome Therapeutics, Inc. | 2 | $240 |
| ABBVIE INC. | 9 | $187 |
| Supernus Pharmaceuticals, Inc. | 6 | $142 |
| Amgen Inc. | 1 | $125 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Novo Nordisk Inc | 1 | $103 |
| Gilead Sciences, Inc. | 1 | $97 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $64 |
Products named: Auvelity, BREZTRI, Qelbree, EVENITY, RELISTOR, CAPLYTA, VRAYLAR, Ozempic.
Industry payments across MS — which companies pay providers there.
